– USA, CA – CellViva, a biopharmaceutical company pioneering the development of an innovative anti-VEGF therapy for pterygium, announced the appointments of Dr. Adrienne Graves, Dr. Kathryn Najafi-Tagol, and Dr. Richard Lindstrom to its Board of Directors.
“We are thrilled to welcome Drs. Graves, Najafi and Lindstrom to our Board of Directors,” said Chair and CEO, Randal Pham. “Their combined knowledge and experience in ophthalmology will be pivotal as we advance our mission to develop a groundbreaking treatment for pterygium.”
About Dr. Adrienne Graves
Dr. Adrienne Graves is the former Board Chair of Iveric Bio and brings decades of experience in clinical development and strategic leadership within the ophthalmology sector. Her insights will be invaluable as CellViva advances its pipeline and prepares for clinical trials.
About Dr. Kathryn Najafi-Tagol
Dr. Kathryn Najafi-Tagol is the Founder of the Eye Institute of Marin, co-inventor of Avenova, a treatment for dry eye associated with blepharitis, and former CMO of NovaBay Pharmaceuticals- She brings extensive clinical and pharmaceutical development experience. Her expertise will be instrumental in addressing significant unmet needs in ophthalmology.
About Dr. Richard Lindstrom
Dr. Richard Lindstrom is a world-renowned cataract and refractive surgeon and founder of Minnesota Eye Consultants. He offers a wealth of knowledge in surgical innovations and industry expertise. His guidance will be critical in steering CellViva’s clinical strategy.
About CellViva
CellViva is a biopharmaceutical company dedicated to developing innovative therapies for ophthalmic and dermatologic conditions.
For more: https://cellviva.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.